1 / 18

Alexander GG Turpie

Comparison of rivaroxaban – an oral, direct Factor Xa inhibitor – and subcutaneous enoxaparin for thromboprophylaxis after total knee replacement. Alexander GG Turpie

EllenMixel
Télécharger la présentation

Alexander GG Turpie

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Comparison of rivaroxaban – an oral, direct Factor Xa inhibitor – and subcutaneous enoxaparin for thromboprophylaxis after total knee replacement Alexander GG Turpie On behalf of Kenneth A Bauer, Scott D Berkowitz, Fred D Cushner, Bruce L Davidson, Michael Gent, Louis M Kwong, Michael R Lassen, Paul A Lotke, Frank Misselwitz, William D Fisher and the RECORD4 Study Investigators

  2. Disclosures for Alexander GG Turpie

  3. Rivaroxaban Rivaroxaban: an oral, direct Factor Xa inhibitor • Once daily • Predictable pharmacokinetics and pharmacodynamics • High oral bioavailability • Rapid onset of action • Fixed dose • No requirement for coagulation monitoring Rivaroxaban binds directly to the active site of Factor Xa (Ki 0.4 nM) Roehrig et al., 2005; Perzborn et al., 2005; Kubitza et al., 2005; 2006; 2007

  4. RECORD: phase III program • Rivaroxaban 10 mg od was compared with enoxaparin in 12,729 patients worldwide

  5. S U R G E R Y RECORD4: study design Double blind F Mandatory bilateral venography Rivaroxaban 10 mg od orally O L 6–8 hours post wound closure or adequate hemostasis L R O W 12–24 hours post wound closure or adequate hemostasis U Enoxaparin 30 mg q12h sc P Day 42+5 Day 1 Day 13±2 Last dose, 1 daybefore venography

  6. Enrolment: 131 sites worldwide Pakistan 1.2% India 15.7% Sri Lanka 1.7% Israel 2.0% United States 49.0% Bulgaria 1.4% Poland 7.8% Lithuania 2.0% Sweden 1.1% Denmark 2.2% Mexico 6.1% US and Canada = 58.8% Canada 9.8%

  7. Study flow Enoxaparin Rivaroxaban Enrolled (N=3418) Randomized (n=3148) 1564 1584 Safety population 1508 1526 mITT population for major VTE* 1122 1112 mITT population for primary efficacy(superiority analysis) 959 965 PP population for primary efficacy†(non-inferiority analysis) 878 864 *Patients may be valid for major VTE analysis if only proximal veins were assessed†Patients could have more than one protocol violation

  8. Patient demographics *Mean values

  9. Efficacy endpoints Primary • Total VTE: any DVT, non-fatal PE, and all-cause mortality up to day 13±4 Secondary • Major VTE: proximal DVT, non-fatal PE, and VTE-related death • DVT: any, proximal, and distal • Symptomatic VTE

  10. Safety endpoints Main • Major bleeding starting after the first blinded dose and up to 2 days after last dose • Bleeding that was fatal, into a critical organ, or required re-operation • Extra-surgical-site bleeding associated with a drop in hemoglobin ≥2 g/dL or requiring transfusion of ≥2 units blood Other • Any bleeding on treatment* • Non-major bleeding* • Hemorrhagic wound complications* • Cardiovascular adverse events • Liver enzyme levels All endpoints were adjudicated centrally by independent, blinded committees *Up to 2 days after last dose of study medication

  11. RRR* = 31.4% ARD† = –3.19% (–5.67, –0.71) p=0.012 14 12 10 8 Incidence (%) 6 4 10.1% 6.9% 2 0 Enoxaparin30 mg q12h97/959 Rivaroxaban10 mg once daily67/965 Primary efficacy endpoint: total VTE *Relative risk reduction based on raw incidences; †absolute weighted risk difference (with 95% CI); mITT population, n=1924

  12. Secondary efficacy endpoints Symptomatic VTE Major VTE 5 5 4 4 ARD = –0.80% (–1.82, 0.22) p=0.124 3 3 ARD = –0.47% (–1.16, 0.23) p=0.187 Incidence (%) Incidence (%) 2 2 1 1 2.0% 1.2% 0.7% 1.2% 0 0 Enoxaparin30 mg q12h 22/1112 Rivaroxaban10 mg once daily 13/1122 Enoxaparin30 mg q12h 18/1508 Rivaroxaban10 mg once daily 11/1526 ARD, absolute weighted risk difference (with 95% CI)

  13. Major bleeding 5 4 p=0.110 3 Incidence (%) 2 0.7% 0.3% 1 0 Enoxaparin30 mg q12h4/1508 Rivaroxaban10 mg once daily10/1526 On-treatment major bleeding; safety population, n=3034

  14. Safety: components of bleeding On-treatment bleeding; *1 patient had fatal post-operative upper GI bleed and a fall in hemogloblin leading to transfusion; † 1intraspinal and 1 intracranial bleed with enoxaparin, 1 retroperitoneal bleed with rivaroxaban; ‡1 subject received only placebo and no active enoxaparin;§all 4 patients had a fall in hemogloblin leading to transfusion; safety population, n=3034

  15. Adverse events *Events occurring more than 1 day after the last intake of study drug during follow-up; safety population

  16. Liver function tests: on-treatment abnormalities Safety population, n=3034; ALT, alanine transaminase; ULN, upper limit of normal; TB, total bilirubin;

  17. RECORD4: summary Total VTE 12 Enoxaparin 30 mg q12h Rivaroxaban 10 mg once daily 10 8 Incidence (%) 6 SymptomaticVTE 4 Major VTE Major bleeding 2 0.7% 0.3% 2.0% 1.2% 10.1% 6.9% 1.2% 0.7% 0 p=0.124 p=0.187 p=0.110 RRR 31% p=0.012 All p-values based on absolute weighted risk differences

  18. RECORD4: conclusions Rivaroxaban demonstrated: • Superior efficacy for the primary endpoint (total VTE) • Low rate of major and symptomatic VTE events • Similar safety profile to enoxaparin • No statistically significant difference in major bleeding • Cardiovascular adverse events low and balanced between groups • No difference in the frequency of abnormal LFTs

More Related